Quantum BioPharma (NASDAQ: QNTM) (CSE: QNTM) has reached the halfway point in patient enrollment for its pilot multiple sclerosis (MS) imaging study conducted with Massachusetts General Hospital. Preliminary PET imaging data from the study show encouraging signals in acute MS lesions, according to a recent article. The novel imaging technique is designed to distinguish demyelinated nerve fibers that may still be viable from permanent nerve damage, potentially offering a more precise way to measure myelin loss and repair.
These findings are directly relevant to Lucid-MS, the company’s investigational compound designed to inhibit demyelination by targeting the enzyme PAD2, which is implicated in myelin degradation. A more precise imaging tool and a drug candidate designed to address the underlying cause of MS make for a compelling combination. Reaching the enrollment midpoint with promising early data suggests the science is holding up under real clinical conditions.
The study's progress is a significant milestone for Quantum BioPharma as it advances its pipeline. The company is dedicated to building a portfolio of innovative assets and biotech solutions for the treatment of challenging neurodegenerative and metabolic disorders, as well as alcohol misuse disorders. Through its wholly owned subsidiary, Lucid Psycheceuticals Inc., Quantum BioPharma is focused on the research and development of Lucid-MS, a patented new chemical entity shown to prevent and reverse myelin degradation in preclinical models.
The potential of this imaging technique extends beyond the current trial. If validated, it could provide a more accurate biomarker for assessing myelin repair in future clinical trials, not only for Lucid-MS but for other remyelinating therapies under development. This could accelerate the path to regulatory approval and bring new treatments to patients faster.
Quantum BioPharma's broader strategy includes its ownership in Unbuzzd Wellness Inc., which markets the OTC version of its unbuzzd product. The company retains 19.84% ownership (as of March 31, 2026) and is entitled to royalty payments of 7% of sales until total payments reach $250 million, after which the royalty drops to 3% in perpetuity. This diversified approach provides multiple value drivers for shareholders.
Investors and stakeholders can access the full article at https://nnw.fm/fsDHa for more detailed insights. For the latest news and updates regarding Quantum BioPharma, visit the company’s newsroom at https://ibn.fm/QNTM.
